APA (7th ed.) Citation

EM, B., DR, M., MT, T., K, W., MI, R., MA, P., . . . RN, A. (2025). Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 43(26), 2856. https://doi.org/10.1200/JCO-25-00494

Chicago Style (17th ed.) Citation

EM, Burton, et al. "Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 43, no. 26 (2025): 2856. https://doi.org/10.1200/JCO-25-00494.

MLA (9th ed.) Citation

EM, Burton, et al. "Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 43, no. 26, 2025, p. 2856, https://doi.org/10.1200/JCO-25-00494.